Pruritus in a diabetic patient, is an indicator of target organ damage?

Sonsoles M Velilla-Zancada; Miguel Ángel Prieto-Díaz

2014, Number 4

<< Back Next >>

Rev Cubana Med Gen Integr 2014; 30 (4)

Pruritus in a diabetic patient, is an indicator of target organ damage?

Velilla-Zancada SM, Prieto-Díaz MÁ

Full text

How to cite this article

Language: Spanish
References: 10
Page: 498-501
PDF size: 46.49 Kb.

ABSTRACT

A seventy-one years-old diabetic and hypertensive male patient with generalized pruritus, probably of uremic etiology, as a result of a rapid deterioration of renal function was presented. After changing the treatment, with improvement in glomerular filtration rate and blood urea levels, clinical signs disappeared and the patient remains asymptomatic.

REFERENCES

American Diabetes Association. Standards of Medical Care in Diabetes 2014. Diabetes Care. 2014;37:s14-s80.
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-57.
Falodun O, Ogunbiyi A, Salako B, George AK. Skin changes in patients with chronic renal failure. Saudi J Kidney Dis Transpl. 2011;22:268-72.
Afsar B, Elsurer Afsar R. HbA1c is related with uremic pruritus in diabetic nondiabetic hemodialysis patients. Ren Fail. 2012;34:1264-9.
Reamy BV, Bunt CW, Eletcher S. A diagnostic approach to pruritus. Am Fam Physician. Jul 15 2011;84:195-202.
Sawada Y, Yoshiki R, Kawakami C, Fukamachi S, Sugita K, Nakamura M, et al. Valsartan-induced Drug Eruption Followed by CD30+ Pseudolymphomatous Eruption. Acta Derm Venerol. 2010;90:521-2.
Yamaoka H, SasaKi H, Yamasaki H, Ogawa K, Ohta T, Furuta H, et al. Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy. Diabetes Care. 2010;33:150-5.
Thomas EA, Pawar B, Thomas A. A prospective study of cutaneous abnormalities in patients with chronic kidney disease. Indian J Nephrol. 2012;22:116-20.
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577-8.
Hamamoto Y, Honjo S, Kawasaki Y, Ikeda H, Mori K, Fujimoto K, et al. Relationship between telmisartan dose and glycaemic control in Japanese patients with type 2 diabetes mellitus and hypertension: a retrospective study. Clin Drug Investig. 2012;32:577-82.